BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7364059)

  • 1. Variation of ethinylestradiol blood levels among healthy women using oral contraceptives.
    Stadel BV; Sternthal PM; Schlesselman JJ; Douglas MB; Hall WD; Kaul L; Ahluwalia B
    Fertil Steril; 1980 Mar; 33(3):257-60. PubMed ID: 7364059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulation of ethinylestradiol in blood and endometrium of women taking oral contraceptives: the sequential therapy.
    Cortés-Gallegos V; Carranco A; Sojo I; Navarrette M; Cervantes C; Parra A
    Fertil Steril; 1979 Nov; 32(5):524-7. PubMed ID: 499582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer risk in relation to type of estrogen contained in oral contraceptives.
    Schlesselman JJ; Stadel BV; Murray P; Lai SH
    Contraception; 1987 Dec; 36(6):595-613. PubMed ID: 3446437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma levels of ethinylestradiol (EE) during cyclic treatment with combined oral contraceptives.
    Kaufman JM; Thiery M; Vermeulen A
    Contraception; 1981 Nov; 24(5):589-602. PubMed ID: 7318439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
    Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
    Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of chronic oral contraceptive steroids on theophylline disposition.
    Tornatore KM; Kanarkowski R; McCarthy TL; Gardner MJ; Yurchak AM; Jusko WJ
    Eur J Clin Pharmacol; 1982; 23(2):129-34. PubMed ID: 7140802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of ethinylestradiol and mestranol in sequential-type oral contraceptives in their effects on blood glucose and serum insulin in oral glucose tolerance tests.
    Leis D; Botterman P; Ermler R; Maurer U
    Fertil Steril; 1977 Jul; 28(7):737-40. PubMed ID: 872954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implications.
    Goldzieher JW
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):318-22. PubMed ID: 2196804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of oral contraceptive steroids after morning or evening administration.
    Kiriwat O; Fotherby K
    Contraception; 1983 Feb; 27(2):153-60. PubMed ID: 6851554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.
    Sinofsky FE; Pasquale SA
    Am J Obstet Gynecol; 1998 Feb; 178(2):300-4. PubMed ID: 9500490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral contraceptives, sex steroid-induced antibodies and vascular thrombosis: results from 1318 cases.
    Beaumont V; Lemort N; Beaumont JL
    Eur Heart J; 1991 Nov; 12(11):1219-24. PubMed ID: 1782953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting pituitary gonadotropin function in users of oral contraceptive steroids.
    Scott JA; Brenner PF; Kletzky OA; Mishell DR
    Am J Obstet Gynecol; 1978 Apr; 130(7):817-21. PubMed ID: 345817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral contraceptives.
    Maclennan AH
    Curr Ther (Seaforth); 1987 Dec; 28(12):113-22. PubMed ID: 12317413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lansoprazole does not affect the bioavailability of oral contraceptives.
    Fuchs W; Sennewald R; Klotz U
    Br J Clin Pharmacol; 1994 Oct; 38(4):376-80. PubMed ID: 7833230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemostatic effects of smoking and oral contraceptive use.
    Fruzzetti F
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S369-74. PubMed ID: 10368523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K; Lunell NO; Zador G
    Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulsatile luteinizing hormone patterns in long term oral contraceptive users.
    Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
    J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.